{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:59:56Z","timestamp":1778155196691,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2012,5,4]],"date-time":"2012-05-04T00:00:00Z","timestamp":1336089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Artif Organs"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>A 58-year-old patient was admitted to the intensive care unit for severe hypercalcemia (total Ca 5.30 mmol\/L) complicated with status epilepticus, hypertensive crisis and acute renal failure. Renal replacement therapy was explored as a method for treating medically refractory hypercalcemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Because of hemodynamic instability during intermittent hemodialysis (IHD), continuous venovenous hemofiltration (CVVH) with high rates of calcium-free replacement fluids was instituted. Epoprostenol rather than citrate was used as anticoagulation to ensure adequate extracorporeal anticoagulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>CVVH was continued for 40 hours total during which ionized calcium decreased from 2.19 to 1.07 mmol\/L. The etiology of the hypercalcemia was from autoinfarction of a parathyroid adenoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This is the first case of hypercalcemia treated with CVVH with epoprostenol anticoagulation. This method avoids some of the pitfalls of using intermittent hemodialysis. It is also a rare example of hypercalcemia induced posterior reversible encephalopathy syndrome (PRES).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5301\/ijao.5000089","type":"journal-article","created":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T08:27:49Z","timestamp":1333614469000},"page":"538-541","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of Medically Refractory Hypercalcemic Crisis"],"prefix":"10.1177","volume":"35","author":[{"given":"Selena","family":"Au","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, University of Calgary, Alberta - Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dunham","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, University of Calgary, Alberta - Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Godinez","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, University of Calgary, Alberta - Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,5,4]]},"reference":[{"key":"bibr1-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V12suppl_1s3"},{"key":"bibr2-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204303261806"},{"issue":"6","key":"bibr3-ijao.5000089","first-page":"285","volume":"12","author":"Cardella C.J.","year":"1979","journal-title":"Clin Nephrol."},{"key":"bibr4-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1007\/BF00255605"},{"key":"bibr5-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1007\/BF01720717"},{"key":"bibr6-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1007\/s001340050562"},{"key":"bibr7-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0b013e31817dc3be"},{"key":"bibr8-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-010-0840-6"},{"key":"bibr9-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20316"},{"key":"bibr10-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0895-x"},{"key":"bibr11-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1080\/00365540510037984"},{"key":"bibr12-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1159\/000086127"},{"key":"bibr13-ijao.5000089","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00861.x"},{"key":"bibr14-ijao.5000089","volume-title":"Compendium of pharmaceuticals and specialties 2011: The Canadian Drug Reference for Health Professionals.","author":"Repchinsky C.","year":"2011"}],"container-title":["The International Journal of Artificial Organs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/ijao.5000089","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/ijao.5000089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:42:20Z","timestamp":1777491740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.5301\/ijao.5000089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,4]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.5301\/ijao.5000089"],"URL":"https:\/\/doi.org\/10.5301\/ijao.5000089","relation":{},"ISSN":["0391-3988","1724-6040"],"issn-type":[{"value":"0391-3988","type":"print"},{"value":"1724-6040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,4]]}}}